drugset / Trial / NCT01694277
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.
Timeline
- Start
- 2012-04
- Primary completion
- 2020-12
- Completion
- 2020-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 12 mg/kg | Oral |
| Comparator | Sunitinib | Small molecule | 50 mg | Oral |